Topography of mutational signatures in human cancer.

CP: Cancer CP: Genomics cancer genomics genome topography mutational signatures somatic mutations

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
29 08 2023
Historique:
received: 16 06 2022
revised: 09 05 2023
accepted: 18 07 2023
medline: 13 9 2023
pubmed: 4 8 2023
entrez: 4 8 2023
Statut: ppublish

Résumé

The somatic mutations found in a cancer genome are imprinted by different mutational processes. Each process exhibits a characteristic mutational signature, which can be affected by the genome architecture. However, the interplay between mutational signatures and topographical genomic features has not been extensively explored. Here, we integrate mutations from 5,120 whole-genome-sequenced tumors from 40 cancer types with 516 topographical features from ENCODE to evaluate the effect of nucleosome occupancy, histone modifications, CTCF binding, replication timing, and transcription/replication strand asymmetries on the cancer-specific accumulation of mutations from distinct mutagenic processes. Most mutational signatures are affected by topographical features, with signatures of related etiologies being similarly affected. Certain signatures exhibit periodic behaviors or cancer-type-specific enrichments/depletions near topographical features, revealing further information about the processes that imprinted them. Our findings, disseminated via the COSMIC (Catalog of Somatic Mutations in Cancer) signatures database, provide a comprehensive online resource for exploring the interactions between mutational signatures and topographical features across human cancer.

Identifiants

pubmed: 37540596
pii: S2211-1247(23)00941-5
doi: 10.1016/j.celrep.2023.112930
pmc: PMC10507738
mid: NIHMS1928262
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

112930

Subventions

Organisme : NCI NIH HHS
ID : R01 CA269919
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES032547
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES030993
Pays : United States
Organisme : Cancer Research UK
ID : C98/A24032
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 108413/A/15/D
Pays : United Kingdom

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests L.B.A. is a compensated consultant and has equity interest in io9, LLC, and Genome Insight. His spouse is an employee of Biotheranostics, Inc. L.B.A. is also an inventor of US patent 10,776,718 for source identification by non-negative matrix factorization. E.N.B. and L.B.A. declare US provisional applications with serial numbers 63/289,601, 63/269,033, and 63/483,237. L.B.A. also declares US provisional applications with serial numbers 63/366,392, 63/412,835, and 63/492,348.

Références

Nat Rev Genet. 2014 Apr;15(4):234-46
pubmed: 24614316
J Biol Chem. 2017 Sep 1;292(35):14456-14472
pubmed: 28717009
BMC Biol. 2022 May 21;20(1):117
pubmed: 35597990
Cell. 2019 Mar 7;176(6):1282-1294.e20
pubmed: 30849372
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Nature. 2003 May 8;423(6936):145-50
pubmed: 12736678
BMC Bioinformatics. 2020 Oct 7;21(1):438
pubmed: 33028213
Gut. 2007 Jun;56(6):763-71
pubmed: 17145738
Cell. 2007 Feb 23;128(4):693-705
pubmed: 17320507
Nature. 2012 Aug 23;488(7412):504-7
pubmed: 22820252
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Nat Genet. 2021 Nov;53(11):1553-1563
pubmed: 34663923
PLoS One. 2015 Feb 11;10(2):e0115686
pubmed: 25671635
BMC Genomics. 2019 Aug 30;20(1):685
pubmed: 31470794
Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3116-23
pubmed: 21282610
Genome Res. 2017 Sep;27(9):1475-1486
pubmed: 28739859
Nat Commun. 2017 Nov 3;8(1):1315
pubmed: 29101368
Nat Genet. 2008 Jul;40(7):897-903
pubmed: 18552846
Nat Commun. 2016 May 02;7:11383
pubmed: 27136393
Nat Genet. 2020 Nov;52(11):1178-1188
pubmed: 33020667
Nature. 2007 Jun 14;447(7146):799-816
pubmed: 17571346
Angew Chem Int Ed Engl. 2016 Jul 18;55(30):8502-27
pubmed: 27337655
Bioinformatics. 2022 Jun 27;38(13):3470-3473
pubmed: 35595234
Cell. 2012 May 25;149(5):979-93
pubmed: 22608084
Cell Rep. 2016 Dec 13;17(11):2865-2872
pubmed: 27974201
Mol Cell. 2013 Mar 7;49(5):825-37
pubmed: 23473601
Genome Biol. 2018 Sep 10;19(1):129
pubmed: 30201020
NAR Cancer. 2020 Sep;2(3):zcaa017
pubmed: 32885167
Mol Cell. 2012 May 25;46(4):424-35
pubmed: 22607975
Nat Genet. 2020 Sep;52(9):958-968
pubmed: 32747826
Nat Genet. 2009 Apr;41(4):393-5
pubmed: 19287383
DNA Repair (Amst). 2020 Jul - Aug;91-92:102868
pubmed: 32438271
Genome Res. 2018 May;28(5):666-675
pubmed: 29636374
Nature. 2020 Sep;585(7825):357-362
pubmed: 32939066
Science. 2016 Nov 4;354(6312):618-622
pubmed: 27811275
FASEB J. 2021 Aug;35(8):e21781
pubmed: 34309923
Ann Oncol. 2018 Apr 1;29(4):938-944
pubmed: 29351612
Genome Res. 2010 Apr;20(4):447-57
pubmed: 20103589
Genome Res. 2019 Apr;29(4):521-531
pubmed: 30846532
Nat Methods. 2020 Mar;17(3):261-272
pubmed: 32015543
Epigenetics Chromatin. 2019 Jun 14;12(1):37
pubmed: 31200754
DNA Repair (Amst). 2008 Mar 1;7(3):497-506
pubmed: 18242151
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Epigenetics Chromatin. 2015 Jan 15;8:3
pubmed: 25788984
Nature. 2009 Apr 9;458(7239):719-24
pubmed: 19360079
Hum Mol Genet. 2002 Jan 1;11(1):13-21
pubmed: 11772995
Cell Genom. 2022 Nov 09;2(11):None
pubmed: 36388765
Nat Commun. 2021 Jun 15;12(1):3628
pubmed: 34131135
Nat Commun. 2017 May 26;8:15290
pubmed: 28548104
Nat Genet. 2021 Sep;53(9):1348-1359
pubmed: 34493867
Cell. 2019 May 2;177(4):821-836.e16
pubmed: 30982602
Nat Commun. 2019 Oct 8;10(1):4571
pubmed: 31594944
J Biol Chem. 1998 May 1;273(18):11069-74
pubmed: 9556591
Nat Commun. 2021 Jan 29;12(1):719
pubmed: 33514712
Science. 2015 Sep 25;349(6255):1483-9
pubmed: 26404825
J Mol Biol. 2002 Jun 21;319(5):1097-113
pubmed: 12079350
Cell. 2016 Jan 28;164(3):538-49
pubmed: 26806129
Am J Hum Genet. 2012 Dec 7;91(6):1033-40
pubmed: 23176822
Cell. 2018 Nov 1;175(4):1074-1087.e18
pubmed: 30388444
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nature. 2022 Feb;602(7897):510-517
pubmed: 35140399
DNA Repair (Amst). 2020 Oct;94:102905
pubmed: 32818816
Genomics. 2014 Feb-Mar;103(2-3):222-8
pubmed: 24530516
Nature. 2015 Feb 19;518(7539):360-364
pubmed: 25693567
Nat Rev Genet. 2014 Sep;15(9):585-98
pubmed: 24981601
Genome Res. 2019 Jul;29(7):1067-1077
pubmed: 31221724
Nature. 2015 May 7;521(7550):81-4
pubmed: 25707793
Nature. 2022 Jul;607(7920):799-807
pubmed: 35859169
DNA Repair (Amst). 2018 Nov;71:6-11
pubmed: 30236628
Cell Biosci. 2020 Jan 31;10:9
pubmed: 32021684

Auteurs

Burçak Otlu (B)

Department of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA 92093, USA; Department of Bioengineering, UC San Diego, La Jolla, CA 92093, USA; Moores Cancer Center, UC San Diego, La Jolla, CA 92037, USA; Department of Health Informatics, Graduate School of Informatics, Middle East Technical University, Ankara 06800, Turkey.

Marcos Díaz-Gay (M)

Department of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA 92093, USA; Department of Bioengineering, UC San Diego, La Jolla, CA 92093, USA; Moores Cancer Center, UC San Diego, La Jolla, CA 92037, USA.

Ian Vermes (I)

COSMIC, Wellcome Sanger Institute, Hinxton, Cambridgeshire CB10 1SA, UK.

Erik N Bergstrom (EN)

Department of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA 92093, USA; Department of Bioengineering, UC San Diego, La Jolla, CA 92093, USA; Moores Cancer Center, UC San Diego, La Jolla, CA 92037, USA.

Maria Zhivagui (M)

Department of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA 92093, USA; Department of Bioengineering, UC San Diego, La Jolla, CA 92093, USA; Moores Cancer Center, UC San Diego, La Jolla, CA 92037, USA.

Mark Barnes (M)

Department of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA 92093, USA; Department of Bioengineering, UC San Diego, La Jolla, CA 92093, USA; Moores Cancer Center, UC San Diego, La Jolla, CA 92037, USA.

Ludmil B Alexandrov (LB)

Department of Cellular and Molecular Medicine, UC San Diego, La Jolla, CA 92093, USA; Department of Bioengineering, UC San Diego, La Jolla, CA 92093, USA; Moores Cancer Center, UC San Diego, La Jolla, CA 92037, USA. Electronic address: L2alexandrov@health.ucsd.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH